AURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aura Biosciences Inc (AURA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive indicators, such as hedge fund buying and bullish moving averages, the lack of significant recent news, weak financial performance, and no strong trading signals suggest holding off on this stock for now.
The MACD is positive at 0.0264, indicating a bullish trend, but it is contracting. RSI is at 75.222, which is neutral. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near resistance levels (R1: 7.116). However, the stock's candlestick pattern suggests a 60% chance of a minor gain of 1.29% in the next day but a decline of -2.93% in the next week.
Hedge funds are significantly increasing their positions, with a 593.96% increase in buying activity over the last quarter. Analysts have raised the price target to $15 from $13, maintaining an Outperform rating.
No recent news or event-driven catalysts. Insider trading activity is neutral. The financial performance in Q4 2025 shows no revenue growth and a significant decline in net income (-1.06% YoY) and EPS (-26.92% YoY).
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$25.56 million (-1.06% YoY), and a significant EPS drop to -0.38 (-26.92% YoY). Gross margin remains at 0%.
Evercore ISI analyst Jonathan Miller raised the price target to $15 from $13 and maintained an Outperform rating. This indicates optimism among analysts but is not enough to offset other negative factors.
